OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
September 09, 2020
The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.
The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.
September 02, 2020
Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain.
September 01, 2020
Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.
August 21, 2020
CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2.
August 13, 2020
The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.
July 23, 2020
Fujifilm Diosynth Biotechnologies’ North Carolina site will be used to manufacture Novavax’ NVX‑CoV2373 vaccine candidate for a Phase III clinical trial.
July 21, 2020
Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.
Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.
July 01, 2020
The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.